SEC Form 4 · accession 0001209191-15-054325
BIODELIVERY SCIENCES INTERNATIONAL INC · BDSI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark A Sirgo
Officer — President and CEO · Director
Period of report
Jun 15, 2015
Accepted (ET)
Jun 17, 2015 · 6:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001103021
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 15, 2015 | A | 8,189 | $0.00 | A | 1,070,826 | D | |
| Common StockF3 | Jun 16, 2015 | S | 4,187 | $7.97 | D | 1,066,639 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of restricted stock units granted under the Registrant's Performance Long Term Incentive Plan.
- F2The shares of common stock were sold under a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs.
- F3On June 16, 2015, the Reporting Person sold an aggregate of 4,187 shares of the Issuer's Common Stock at a weighted average price of $7.97. The highest sale price for the Common Stock was $8.13 per share and the lowest sale price was $7.89 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.